Neeta Somaiah, MD

Peer-Reviewed Articles

1. Patel RR, Feit J, Werling G, White NM, Bishop AJ, Lin PP, Valenzuela Perez RF, Lazar AJ, Benjamin RS, Patel SR, Ludwig J, Ravi V, Livingston JA, Zarzour MA, Conley A, Somaiah N, Araujo DM. Primary Synovial Sarcoma of the Abdomen and Pelvis. Am J Clin Oncol, 2025. e-Pub 2025. PMID: 41342607.
2. Hu, J, Singh, H, Jin, Y, Zhang, W, Wang, J, Xia, X, Somaiah, N, Gorlick, R, Li, S. Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. Proceedings of the National Academy of Sciences of the United States of America 122(41), 2025. e-Pub 2025. PMID: 41052334.
3. Traweek RS, Zoghbi M, Lazcano R, Cope BM, Bishop AJ, Farooqi A, Mitra D, Yoder AK, Guadagnolo BA, Ingram DR, Wani K, Shamsutdinova D, Lazar AJ, Wang WL, Scally CP, Keung EZ, Torres KE, Hunt KK, Ratan R, Livingston JA, Nakazawa MS, Araujo DM, Patel S, Ravi V, Conley AP, Zarzour MA, Somaiah N, Roland CL, Nassif Haddad EF. Hyalinization-based pathologic response and immune infiltration following neoadjuvant radiotherapy with or without immune-checkpoint blockade in localized undifferentiated pleomorphic sarcoma. ESMO Open 10(7):105493, 2025. e-Pub 2025. PMID: 40561658.
4. D'Angelo SP, Druta M, Van Tine BA, Liebner D, Schuetze SM, Tap WD, Preston J, Goodison S, D'Souza JW, Kapoor GS, Suchindran S, Zajic S, Bhaskar A, Kaczynski H, Kim J, Klohe E, Corigliano E, Eleftheriadou I, Nathenson MJ, Somaiah N. Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma. J Clin Oncol 43(15):1777-1788, 2025. e-Pub 2025. PMID: 39836945.
5. Bishop AJ, Mitra D, Farooqi A, Swanson DM, Hempel C, Willis T, Pearlnath C, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Guadagnolo BA. Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomes. Cancer 131(1):e35542, 2025. e-Pub 2025. PMID: 39192597.
6. Patel RR, Delclos GL, DeSantis SM, Cannell MB, Lupo PJ, Bishop AJ, Lazar AJ, Lin PP, Benjamin RS, Patel SR, Ludwig J, Ravi V, Livingston JA, Somaiah N, Zarzour MA, Conley AP, Araujo DM. Does the Primary Tumor Site Drive Biology for Patients With Synovial Sarcoma?. Am J Clin Oncol 48(1):21-27, 2025. e-Pub 2025. PMID: 39224003.
7. Torres MB, Leung CH, Zoghbi M, Lazcano R, Ingram D, Wani K, Keung EZ, Zarzour MA, Scally CP, Hunt KK, Conley A, Bishop AJ, Guadagnolo BA, Farooqi A, Mitra D, Yoder AK, Nakazawa MS, Araujo D, Livingston A, Ratan R, Patel S, Ravi V, Lazar AJ, Roland CL, Somaiah N, Nassif Haddad EF. Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience. Front Immunol 16:1567736, 2025. e-Pub 2025. PMID: 40370451.
8. Jin Y, Jia Z, Xia X, Gordon NB, Ludwig JA, Somaiah N, Li S. Anti-CD137 agonist antibody-independent and clinically feasible preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma. Front Immunol 16:1557006, 2025. e-Pub 2025. PMID: 40145091.
9. Lyu HG, Witt RG, Rajkot N, Keung EZ, Torres KE, Hunt KK, Somaiah N, Lazar AJ, Roland CL, Scally CP. Patterns of Care and Outcomes of Patients with Small Gastrointestinal Stromal Tumors at a High-Volume Sarcoma Center. Ann Surg Oncol 31(13):9258-9264, 2024. e-Pub 2024. PMID: 39230849.
10. Pal K, Awad A, Yevich S, Kuban JD, Tam A, Huang SY, Odisio BC, Gupta S, Habibollahi P, Bishop AJ, Conley AP, Somaiah N, Araujo D, Zarzour MA, Ravin R, Roland CL, Keung EZ, Sheth RA. Safety and Efficacy of Percutaneous Cryoablation for Recurrent or Metastatic Soft Tissue Sarcoma in Adult Patients. American Journal of Roentgenology 223(4), 2024. e-Pub 2024. PMID: 39082849.
11. Martiniova, L, Kamel, S, Kairemo, K, Benjamin, RS, Somaiah, N, Ravizzini, G, Nassif, EF. Predictive Value of Quantitative Parameters of 18F-FDG PET/CT in Patients with Liposarcoma. Diagnostics 14(18), 2024. e-Pub 2024. PMID: 39335700.
12. Denu RA, Somaiah N. Imatinib in advanced GIST: if it's working, don't stop a good thing. Lancet Oncol 25(9):1105-1107, 2024. e-Pub 2024. PMID: 39127065.
13. Awad A, Pal K, Yevich S, Kuban JD, Tam A, Odisio BC, Gupta S, Habibollahi P, Bishop AJ, Conley AP, Somaiah N, Araujo DM, Zarzour MA, Ratan R, Roland CL, Keung EZ, Huang SY, Sheth RA. Safety and efficacy of percutaneous image-guided ablation for soft tissue sarcoma metastases to the liver. Cancer 130(15):2703-2712, 2024. e-Pub 2024. PMID: 38642369.
14. Truong DD, Weistuch C, Murgas KA, Admane P, King BL, Chauviere Lee J, Lamhamedi-Cherradi SE, Swaminathan J, Daw NC, Gordon N, Gopalakrishnan V, Gorlick RG, Somaiah N, Deasy JO, Mikos AG, Tannenbaum A, Ludwig J. Mapping the Single-cell Differentiation Landscape of Osteosarcoma. Clin Cancer Res 30(15):3259-3272, 2024. e-Pub 2024. PMID: 38775859.
15. Piha-Paul SA, Tseng C, Leung CH, Yuan Y, Karp DD, Subbiah V, Hong D, Fu S, Naing A, Rodon J, Javle M, Ajani JA, Raghav KP, Somaiah N, Mills GB, Tsimberidou AM, Zheng X, Chen K, Meric-Bernstam F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ Precis Oncol 8(1):166, 2024. e-Pub 2024. PMID: 39085400.
16. Nasr LF, Zoghbi M, Lazcano R, Nakazawa M, Bishop AJ, Farooqi A, Mitra D, Guadagnolo BA, Benjamin R, Patel S, Ravi V, Araujo DM, Livingston A, Zarzour MA, Conley AP, Ratan R, Somaiah N, Lazar AJ, Roland C, Keung EZ, Nassif Haddad EF. High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel) 16(9), 2024. e-Pub 2024. PMID: 38730715.
17. Denu RA, Joseph CP, Urquiola ES, Byrd PS, Yang RK, Ratan R, Zarzour MA, Conley AP, Araujo DM, Ravi V, Nassif Haddad EF, Nakazawa MS, Patel S, Wang WL, Lazar AJ, Somaiah N. Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors. Cancers (Basel) 16(9), 2024. e-Pub 2024. PMID: 38730662.
18. Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer 5(4):625-641, 2024. e-Pub 2024. PMID: 38351182.
19. Farooqi AS, Yoder AK, Lin HY, Pasalic D, Erasmus J, Betancourt S, Wernz C, Mitra D, Zarzour MA, Somaiah N, Conley A, Ratan R, Livingston A, Araujo DM, Roland C, Scally C, Keung E, Gandhi SN, Ashleigh Guadagnolo B, Nguyen QN, Bishop AJ. SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. Int J Radiat Oncol Biol Phys 118(4):971-978, 2024. e-Pub 2024. PMID: 37914142.
20. Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah N. Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473266.
21. Waguespack SG, Somaiah N, Lee JE, Elsayes KM. Incomplete Carney Triad. JCEM Case Rep 2(2):luae016, 2024. e-Pub 2024. PMID: 38405102.
22. Heinrich MC, Jones RL, George S, Gelderblom H, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Blay JY, Bauer S. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med 30(2):498-506, 2024. e-Pub 2024. PMID: 38182785.
23. Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay JY, Sicklick JK, Schwartz GK, Rastogi S, Jones RL, Rutkowski P, Somaiah N, Navarro V, Evans D, Trent JC. Novel trial designs for patients with gastrointestinal stromal tumor. ESMO Open 9(1):102218, 2024. e-Pub 2024. PMID: 38194880.
24. Nakazawa MS, Livingston JA, Zarzour MA, Bishop AJ, Ratan R, Ludwig JA, Araujo DM, Somaiah N, Ravi V, Nassif EF, Roland CL, Lazar AJ, Guadagnolo BA, Harrison DJ, Benjamin RS, Patel SR, Conley AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors 16:20363613241271669, 2024. e-Pub 2024. PMID: 39105190.
25. George S, Blay JY, Chi P, Jones RL, Serrano C, Somaiah N, Gelderblom H, Zalcberg JR, Reichmann W, Sprott K, Cox P, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations. Future Oncol 20(27):1973-1982, 2024. e-Pub 2024. PMID: 39229786.
26. Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay JY, Sicklick JK, Schwartz GK, Rastogi S, Jones RL, Rutkowski P, Somaiah N, Navarro V, Evans D, Trent JC. Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors. Nat Med 29(11):2689-2692, 2023. e-Pub 2023. PMID: 37828359.
27. Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S, investigators I. Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. Eur J Cancer 192:113245, 2023. e-Pub 2023. PMID: 37598656.
28. George S, Heinrich MC, Somaiah N, Oppelt P, McLeod R, Nishioka S, Kundu MG, Qian X, Kumar P, Laadem A, Lau Y, Tran BP, Fallon M, Dosunmu O, Shi J, Naito Y. A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor. Clin Cancer Res 29(18):3659-3667, 2023. e-Pub 2023. PMID: 37363962.
29. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Ileana Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer 129(14):2201-2213, 2023. e-Pub 2023. PMID: 37016732.
30. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. e-Pub 2023. PMID: 37058010.
31. Nguyen TDT, Wang Y, Bui TN, Lazcano R, Ingram DR, Yi M, Vakulabharanam V, Luo L, Pina MA, Karakas C, Li M, Kettner NM, Somaiah N, Houghton PJ, Mawlawi O, Lazar AJ, Hunt KK, Keyomarsi K. Sequential targeting of retinoblastoma and DNA synthesis pathways is a therapeutic strategy for sarcomas that can be monitored in real-time. Cancer Res 83(6):939-955, 2023. e-Pub 2023. PMID: 36603130.
32. Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC, Stephen Hodi F, Schellens JHM, Litton JK, Aspeslagh S, Autio KA, Opdam FL, McKean M, Somaiah N, Champiat S, Altan M, Spreafico A, Rahma O, Paul EM, Ahlers CM, Zhou H, Struemper H, Gorman SA, Watmuff M, Yablonski KM, Yanamandra N, Chisamore MJ, Schmidt EV, Hoos A, Marabelle A, Weber JS, Heymach JV. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36927527.
33. Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med 12(4):4282-4293, 2023. e-Pub 2022. PMID: 36151848.
34. Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res 29(2):401-409, 2023. e-Pub 2023. PMID: 36288393.
35. Nassif EF, Joseph CP, Lazcano R, Joseph JT, Thirasastr P, Lazar AJ, Somaiah N. Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas. Front Oncol 13:1046442, 2023. e-Pub 2023. PMID: 36845725.
36. Gouda MA, Janku F, Somaiah N, Hunt KK, Yedururi S, Subbiah V. Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery. Oncoscience 10:38-43, 2023. e-Pub 2023. PMID: 37736254.
37. Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol 23(12):1547-1557, 2022. e-Pub 2022. PMID: 36343656.
38. Thiebaud JA, Ravi V, Litwin S, Schuetze SM, Movva S, Agulnik M, Kraft AS, Tetzlaff ED, Somaiah N, von Mehren M. OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer 128(19):3516-3522, 2022. e-Pub 2022. PMID: 35942596.
39. Bishop AJ, Amini B, Lin H, Raza SM, Patel S, Grosshans DR, Ghia A, Farooqi A, Guadagnolo BA, Mitra D, Akdemir KC, Lazar AJ, Wang WL, Alvarez-Breckenridge C, Bird J, Rhines LD, Somaiah N, Conley AP. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother 45(8):374-378, 2022. e-Pub 2022. PMID: 35943386.
40. Nathenson MJ, Hu J, Ratan R, Somaiah N, Hsu R, DeMaria PJ, Catoe HW, Pang A, Subhawong TK, Amini B, Sweet K, Feister K, Malik K, Jagannathan J, Braschi-Amirfarzan M, Sheren J, Caldas Y, Moreno Tellez C, Rosenberg AE, Lazar AJ, Maki RG, Benedetto P, Cohen J, Trent JC, Ravi V, Patel S, Wilky BA. Systemic chemotherapies retain anti-tumor activity in desmoid tumors independent of specific mutations in CTNNB1 or APC: A multi-institutional retrospective study. Clin Cancer Res 28(18):4092-4104, 2022. e-Pub 2022. PMID: 35180772.
41. Ravi V, Subramaniam A, Zheng J, Amini B, Trinh VA, Joseph J, Mennel RG, Bishop AJ, Sturgis EM, Goepfert RP, Yalamanchili S, Botello G, Stephen B, Piha-Paul SA, Patel AB, Lazar AJ, Conley AP, Benjamin RS, Patel SR, Futreal PA, Somaiah N, Naing A. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer 128(18):3383-3391, 2022. e-Pub 2022. PMID: 35792683.
42. Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol 23(9):1156-1166, 2022. e-Pub 2022. PMID: 35934010.
43. Gounder MM, Agaram NP, Trabucco SE, Robinson V, Ferraro RA, Millis SZ, Krishnan A, Lee J, Attia S, Abida W, Drilon A, Chi P, Angelo SP, Dickson MA, Keohan ML, Kelly CM, Agulnik M, Chawla SP, Choy E, Chugh R, Meyer CF, Myer PA, Moore JL, Okimoto RA, Pollock RE, Ravi V, Singh AS, Somaiah N, Wagner AJ, Healey JH, Frampton GM, Venstrom JM, Ross JS, Ladanyi M, Singer S, Brennan MF, Schwartz GK, Lazar AJ, Thomas DM, Maki RG, Tap WD, Ali SM, Jin DX. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun 13(1):3406, 2022. e-Pub 2022. PMID: 35705558.
44. Boyce-Fappiano D, Damron EP, Farooqi A, Mitra D, Conley AP, Somaiah N, Araujo DM, Livingston JA, Ratan R, Keung EZ, Roland CL, Guadagnolo BA, Bishop AJ. Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. Adv Radiat Oncol 7(3):100913, 2022. e-Pub 2022. PMID: 35647398.
45. Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol:JCO2101829. e-Pub 2022. PMID: 35394800.
46. Thirasastr P, Somaiah N. Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma. Therapeutic Advances in Medical Oncology, 2022. e-Pub 2022.
47. Nassif EF, Cope B, Traweek R, Witt RG, Erstad DJ, Scally CP, Thirasastr P, Zarzour MA, Ludwig J, Benjamin R, Bishop AJ, Guadagnolo B, Ingram D, Wani K, Wang W, Lazar AJ, Torres KE, Hunt KK, Feig BW, Roland CL, Somaiah N, Keung EZ. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. International Journal of Cancer, 2022. e-Pub 2022.
48. Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12:1008484, 2022. e-Pub 2022. PMID: 36313661.
49. Voss RK, Massarweh NN, Chiang YJ, Somaiah N, Feig BW, Roland CL. ASO Visual Abstract: National Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors. Ann Surg Oncol 28(Suppl 3):457, 2021. e-Pub 2021. PMID: 34050428.
50. Voss RK, Massarweh NN, Chiang YJ, Somaiah N, Feig BW, Roland CL. National Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors. Ann Surg Oncol 28(13):9159-9168, 2021. e-Pub 2021. PMID: 34046772.
51. Zalcberg JR, Heinrich MC, George S, Bauer S, Schöffski P, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Somaiah N, Meade J, Reichert V, Shi K, Sherman ML, Ruiz-Soto R, von Mehren M, Blay JY. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist 26(11):e2053-e2060, 2021. e-Pub 2021. PMID: 34313371.
52. George S, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Razak AA, Gordon MS, Somaiah N, Jennings J, Meade J, Shi K, Su Y, Ruiz-Soto R, Janku F. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer 155:236-244, 2021. e-Pub 2021. PMID: 34391056.
53. Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia S. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncol 17(22):2923-2939, 2021. e-Pub 2021. PMID: 33855868.
54. Parkes A, Wang WL, Patel S, Leung CH, Lin H, Conley AP, Somaiah N, Araujo DM, Zarzour M, Livingston JA, Ludwig J, Roland CL, Ravi V, Benjamin RS, Ratan R. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat 186(3):871-882, 2021. e-Pub 2021. PMID: 33575859.
55. Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer 127(6):894-904, 2021. e-Pub 2021. PMID: 33231866.
56. Kasper B, Achee A, Schuster K, Wilson R, Oortmerssen GV, Gladdy RA, Hemming ML, Huang P, Ingham M, Jones RL, Pollack SM, Reinke D, Sanfilippo R, Schuetze SM, Somaiah N, Van Tine BA, Wilky B, Okuno S, Trent J. Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers (MDPI) 13(4), 2021. e-Pub 2021.
57. Keung EZ, Rajkot N, Torres KE, Somaiah N, Hunt KK, Feig BW, Scally CP, Ikoma N, Roland CL. Evaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum. Ann Surg Oncol 28(1):570-575, 2021. e-Pub 2021. PMID: 32409969.
58. Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Ter Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. Oncoimmunology 9(1):1847846, 2020. e-Pub 2020. PMID: 33312760.
59. Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George S. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol 38(28):3294-3303, 2020. e-Pub 2020. PMID: 32804590.
60. Pollack SM, Somaiah N, Araujo DM, Druta M, Van Tine BA, Burgess MA, Chawla SP, Seetharam M, Okuno SH, Bohac C, Chen M, Yurasov S, Attia S. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med 9(13):4593-4602, 2020. e-Pub 2020. PMID: 32374488.
61. Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah V. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther 19(5):1165-1172, 2020. e-Pub 2020. PMID: 32127467.
62. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008, 2020. e-Pub 2020. PMID: 32081846.
63. Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma 2020:8363986, 2020. e-Pub 2020. PMID: 32565716.
64. Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Incidence and Management of Olaratumab Infusion-Related Reactions. J Oncol Pract 15(11):e925-e933, 2019. e-Pub 2019. PMID: 31268811.
65. Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen JH, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SM. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res 25(19):5808-5817, 2019. e-Pub 2019. PMID: 31227504.
66. Chrisinger JSA, Al-Zaid T, Keung EZ, Leung C, Lin HY, Roland CL, Torres KE, Benjamin RS, Ingram DR, Khan S, Somaiah N, Amini B, Feig BW, Lazar AJ, Wang WL. The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol 120(3):382-388, 2019. e-Pub 2019. PMID: 31206726.
67. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. Clin Cancer Res 25(13):3802-3810, 2019. e-Pub 2019. PMID: 30733229.
68. Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31096717.
69. Keung Z, Somaiah N. Overview of liposarcomas and their genomic landscape. J Transl Genet Genom, 2019. e-Pub 2019.
70. Wilkins A, Melcher A, Somaiah N. Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology. Clin Oncol (R Coll Radiol) 30(10):605-608, 2018. e-Pub 2018. PMID: 30041845.
71. Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CL. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer 18(1):913, 2018. e-Pub 2018. PMID: 30249211.
72. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget 9(69):33232-33243, 2018. e-Pub 2018. PMID: 30237864.
73. Conley AP, Trinh VA, Zobniw CM, Posey K, Martinez JD, Arrieta OG, Wang WL, Lazar AJ, Somaiah N, Roszik J, Patel SR. Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. J Glob Oncol DOI: 10.1200/JGO.2017.009993:1-6, 2018. e-Pub 2018. PMID: 30241159.
74. Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit. Ann Surg Oncol 25(8):2193-2200, 2018. e-Pub 2018. PMID: 29520652.
75. Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center. J Surg Oncol 117(6):1188-1194, 2018. e-Pub 2018. PMID: 29228466.
76. Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 9(28):19891-19899, 2018. e-Pub 2018. PMID: 29731991.
77. Beird HC, Wu CC, Ingram DR, Wang WL, Alimohamed A, Gumbs C, Little L, Song X, Feig BW, Roland CL, Zhang J, Benjamin RS, Hwu P, Lazar AJ, Futreal PA, Somaiah N. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Cold Spring Harb Mol Case Stud 4(2), 2018. e-Pub 2018. PMID: 29610390.
78. Roland CL, Bednarski BK, Watson K, Torres KE, Cormier JN, Wang WL, Lazar AJ, Somaiah N, Hunt KK, Feig BW. Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol 117(5):879-885, 2018. e-Pub 2018. PMID: 29448300.
79. Zobniw CM, Trinh VA, Posey K, Somaiah N. Olaratumab in the management of advanced soft tissue sarcoma. J Oncol Pharm Pract((2)):442-448, 2018. e-Pub 2018. PMID: 30032714.
80. Goumard C, Marcal LP, Wang WL, Somaiah N, Okuno M, Roland CL, Tzeng CD, Chun YS, Feig BW, Vauthey JN, Conrad C. Long-Term Survival According to Histology and Radiologic Response to Preoperative Chemotherapy in 126 Patients Undergoing Resection of Non-GIST Sarcoma Liver Metastases. Ann Surg Oncol 25(1):107-116, 2018. e-Pub 2018. PMID: 29116489.
81. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist 23(1):62-70, 2018. e-Pub 2018. PMID: 28754721.
82. Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hunt KK, Wargo JA, Lazar AJ, Wang WL, Roland CL. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology 7(2):e1385689, 2018. e-Pub 2018. PMID: 29308306.
83. Li H, Meng QH, Noh H, Somaiah N, Torres KE, Xia X, Batth IS, Joseph CP, Liu M, Wang R, Li S. Cell-surface vimentin-positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors. Oncoimmunology 7(5):e1420450, 2018. e-Pub 2018. PMID: 29721368.
84. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 5(1):100, 2017. e-Pub 2017. PMID: 29254498.
85. Samuels BL, Chawla SP, Somaiah N, Staddon AP, Skubitz KM, Milhem MM, Kaiser PE, Portnoy DC, Priebat DA, Walker MS, Stepanski EJ. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer 123(23):4640-4647, 2017. e-Pub 2017. PMID: 28832986.
86. Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 7(1):15963, 2017. e-Pub 2017. PMID: 29162825.
87. Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist 22(10):1271-1277, 2017. e-Pub 2017. PMID: 28710342.
88. Reddy N, Moudgil R, Lopez-Mattei JC, Karimzad K, Mouhayar EN, Somaiah N, Conley AP, Patel S, Giza DE, Iliescu C. Progressive and Reversible Conduction Disease with Checkpoint Inhibitors. Can J Cardiol 33(10):1335.e13-1335.e15, 2017. e-Pub 2017. PMID: 28822650.
89. Pollack SM, Lu H, Gnjatic S, Somaiah N, O'Malley RB, Jones RL, Hsu FJ, Ter Meulen J. First-in-Human Treatment with a Dendritic Cell-Targeting Lentiviral Vector expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. J Immunother 40(8):302-306, 2017. e-Pub 2017. PMID: 28891906.
90. Li H, Meng QH, Noh H, Batth IS, Somaiah N, Torres KE, Xia X, Wang R, Li S. Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. Cancer Lett Jun 23;403:216-223. doi:10.1016/j.canlet.2017.05.032:216-223, 2017. e-Pub 2017. PMID: 28652021.
91. Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK. CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest. Mol Cancer Ther 16(9):1751-1764, 2017. e-Pub 2017. PMID: 28619757.
92. Schvartsman G, Wagner MJ, Amini B, Zobniw CM, Trinh VA, Barbo AG, Lin HY, Wang WL, Conley AP, Ravi V, Araujo DM, Zarzour MA, Benjamin RS, Patel S, Somaiah N. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep 7(1):9519, 2017. e-Pub 2017. PMID: 28842575.
93. Jalal SI, Hanna N, Zon R, Masters GA, Borghaei H, Koneru K, Badve S, Prasad N, Somaiah N, Wu J, Yu Z, Einhorn L. Phase I Study of Amrubicin and Cyclophosphamide Patients with Advanced Solid Organ Malignancies: HOG LUN 07-130. Am J Clin Oncol 40(4):329-335, 2017. e-Pub 2017. PMID: 25503432.
94. de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, JVMG B. High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. Transl Oncol 10(4):546-554, 2017. e-Pub 2017. PMID: 28654818.
95. Al-Zaid T, Wang WL, Somaiah N, Lazar AJ. Molecular profiling of sarcomas: new vistas for precision medicine. Virchows Arch doi:10.1007/s00428-017-2174-3. e-Pub 2017. PMID: 28664413.
96. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 8(24):39254-39267, 2017. e-Pub 2017. PMID: 28424409.
97. Samuels BL, Chawla S, Somaiah N, Staddon A, Skubitz K, Milhem M, Kaiser P, Portnoy D, Priebat D, Walker MS, Stepanski EJ. Results of a Prospective Phase II Study of Pazopanib in Patients with Advanced Intermediate- or High-Grade Liposarcoma (CNCR-17-0785.R1). Cancer. Accepted, 2017. e-Pub 2017.
98. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma (ASPS). The Oncologist, 2017. e-Pub 2017.
99. Farag S, Somaiah N, Choi H, Heeres B, Wang WL, van Boven H, Nederlof P, Benjamin R, van der Graaf W, Grunhagen D, Boonstra PA, Reyners AK, Gelderblom H, Steeghs N. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Eur J Cancer 76:76-83, 2017. e-Pub 2017. PMID: 28284172.
100. Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch H, Fancourt C, Johnson-Levonas AO, Lam R, Meister AK, Russo G, Knox CD, Rose S, Hong DS. Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. J Clin Oncol 35(12):1304-1311, 2017. e-Pub 2017. PMID: 28240971.
101. Livingston JA, Bugano D, Barbo A, Lin H, Madewell JE, Wang WL, Lazar A, Tseng W, Roland CL, Feig B, Pollock R, Conley AP, Benjamin RS, Patel SR, Somaiah N. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Accepted with revisions. Scientific reports, 2017. e-Pub 2017.
102. Quintana RA, Banchs J, Gupta R, Lin HY, Raj SD, Conley A, Ravi V, Araujo D, Benjamin RS, Patel S, Vadhan-Raj S, Somaiah N. Early evidence of cardiotoxicity and tumor response in patients with sarcomas after high cumulative dose doxorubicin given as a continuous infusion. Sarcoma 2017:7495914, 2017. e-Pub 2017. PMID: 29081684.
103. Bhosale P, Wang J, Varma D, Jensen C, Patnana M, Wei W, Chauhan A, Feig B, Patel S, Somaiah N, Sagebiel T. Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma?. J Comput Assist Tomogr 40(6):872-879(6):872-879, 2016. e-Pub 2016. PMID: 27454788.
104. de Graaff MA, Yu JS, Beird HC, Ingram DR, Nguyen T, Juehui Liu J, Bolshakov S, Szuhai K, Åman P, Torres KE, Lev D, Nielsen TO, Bovée JV, Lazar AJ, Somaiah N. Establishment and Characterization of a New Human Myxoid Liposarcoma Cell Line (DL-221) with the FUS-DDIT3 Translocation. Lab Invest Aug;96(8):885-94. doi: 10.1038/labinvest.2016.64(8):885-94, 2016. e-Pub 2016. PMID: 27270875.
105. Endo M, de Graaff MA, Ingram DR, Lim S, Lev DC, Briaire-de Bruijn IH, Somaiah N, Bovée JV, Lazar AJ, Nielsen TO. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol 28(4):587-95, 2015. e-Pub 2015. PMID: 25412843.
106. Ikoma N, Torres KE, Somaiah N, Hunt KK, Cormier JN, Tseng W, Lev D, Pollock R, Wang WL, Feig B. Accuracy of Preoperative Percutaneous Biopsy for the Diagnosis of Retroperitoneal Liposarcoma Subtypes. Ann Surg Oncol 22(4):1068-72, 2015. e-Pub 2015. PMID: 25354575.
107. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol S1-63(1 Suppl 1):S1-63, 2015. e-Pub 2015. PMID: 25535693.
108. Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, Lizée G, Radvanyi L, Hwu P. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma 2015:547460, 2015. e-Pub 2015. PMID: 25705114.
109. Tseng WW, Somaiah N, Engleman EG. Potential for immunotherapy in soft tissue sarcoma. Hum Vaccun Immunother 10(11):3117-24, 2014. e-Pub 2014. PMID: 25412843.
110. Burgoyne AM, Somaiah N, Sicklick JK. Gastrointestinal stromal tumors in the setting of multiple tumor syndromes. Curr Opin Oncol 26(4):408-14, 2014. e-Pub 2014. PMID: 24840526.
111. Tseng WW, Madewell JE, Wei W, Somaiah N, Lazar AJ, Ghadimi MP, Hoffman A, Pisters PW, Lev DC, Pollock RE. Locoregional Disease Patterns in Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcoma: Implications for the Extent of Resection?. Ann Surg Oncol 21(7):2136-43, 2014. e-Pub 2014. PMID: 24705628.
112. Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Res 74(6):1645-50, 2014. e-Pub 2014. PMID: 24448245.
113. Aggarwal C, Li L, Borghaei H, Mehra R, Somaiah N, Turaka A, Langer CJ, Simon GR. Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery. Cancer Control 21(1):57-62, 2014. e-Pub 2014. PMID: 24357742.
114. Simon GR, Somaiah N. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. Clin Lung Cancer 15(1):21-51, 2014. e-Pub 2014. PMID: 24377743.
115. Al-Zaid T, Somaiah N, Lazar AJ. Targeted therapies for sarcomas: new roles for the pathologist. Histopathology 64(1):119-33, 2014. e-Pub 2014. PMID: 24117526.
116. Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience 1(8):522-528, 2014. e-Pub 2014. PMID: 25594059.
117. Tseng WW, Somaiah N, Lazar AJ, Lev DC, Pollock RE. Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel) 5(2):529-49, 2013. e-Pub 2013. PMID: 24216990.
118. Somaiah N, Simon NG, Simon GR. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. J Thorac Oncol 7(16 Suppl 5):S342-68, 2012. e-Pub 2012. PMID: 23160320.
119. Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, Davey M, Bove B, von Mehren M. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol 69(4):977-82, 2012. e-Pub 2012. PMID: 22119758.
120. Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?. Cancer Biol Ther 13(5):247-63, 2012. e-Pub 2012. PMID: 22481432.
121. Somaiah N, von Mehren M. New drugs and combinations for the treatment of soft tissue sarcoma: A review. Cancer Manag Res 2012:4:397-411, 2012. e-Pub 2012. PMID: 23226072.
122. Stinchcombe TE, Baggstrom MQ, Somaiah N, Simon GR, Govindan R. Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010). J Thorac Oncol 6(1):227-32, 2011. e-Pub 2011. PMID: 21178721.
123. Somaiah N, Simon GR. Molecular targeted agents and biologic therapies for non-small cell lung cancer. J Thorac Oncol 5(12 Suppl 6):S434-54, 2010. e-Pub 2010. PMID: 21102235.
124. Biermann JS, Adkins DR, Benjamin RS, Brigman B, Chow W, Conrad EU, Frassica DA, Frassica FJ, George S, Hande KR, Hornicek FJ, Letson GD, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, Somaiah N, Yasko AW, Cancer Panel NCCNB. Bone Cancer. J Natl Compr Canc Netw 8(6):688-712(6):688-712, 2010. e-Pub 2010. PMID: 20581300.
125. Somaiah N, Simon GR. Molecular targeted therapy in non-small cell lung cancer: an overview of available agents. J Thorac Oncol 4(11 Suppl 3):S1046-56, 2009. e-Pub 2009. PMID: 19861914.
126. Banumathy G, Somaiah N, Zhang R, Tang Y, Hoffmann J, Andrake M, Ceulemans H, Schultz D, Marmorstein R, Adams PD. Human UBN1 is an ortholog of yeast Hpc2p and has an essential role in the HIRA/ASF1a chromatin-remodeling pathway in senescent cells. Mol Cell Biol 29(3):758-70, 2009. e-Pub 2009. PMID: 19029251.
127. Ye X, Zerlanko B, Zhang R, Somaiah N, Lipinski M, Salomoni P, Adams PD. Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol 27(7):2452-65, 2007. e-Pub 2007. PMID: 17242198.
128. Singhal R, Angmo N, Somaiah N, Majumdar H, Chaturvedi KU. A retrospective review of the histopathology and clinicopathologic correlates of appendices removed from patients of acute appendicitis. Minerva Chir 62(1):11-8, 2007. e-Pub 2007. PMID: 17287689.

Invited Articles

1. Somaiah N. The Role of Combination Chemotherapy in GIST. GIST Cancer Journal, 2014. e-Pub 2014.

Review Articles

1. Dunker AM, Malik N, Krause KJ, Keung EZ, Liu JB, Nassif Haddad EF, Somaiah N, Lyu HG, Roland CL. Health-Related Quality of Life in the Era of Immune Checkpoint Blockade: What Do Patient-Reported Outcomes Reveal?. Cancers (Basel) 17(24), 2025. e-Pub 2025. PMID: 41463169.
2. Torrado C, Nassif Haddad E, Somaiah N, Msaouel P, Lazar AJ, Piha-Paul SA. Advancing Understanding and Therapeutic Strategies for NUT Sarcomas: Comprehensive Review of the Literature and Two Cases. J Immunother Precis Oncol 8(2):113-120, 2025. e-Pub 2025. PMID: 40070529.
3. Somaiah N, Paudyal B, Winkler RE, Van Tine BA, Hirbe AC. Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents. Target Oncol 19(5):665-678, 2024. e-Pub 2024. PMID: 38954182.
4. Somaiah N, Tap W. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action. Cancer Treat Rev 122:102668, 2024. e-Pub 2024. PMID: 38104352.
5. Nassif, EF, Keung, EZ, Thirasastr, P, Somaiah, N. Myxoid Liposarcomas. Current treatment options in oncology 24(4):274-291, 2023. e-Pub 2023. PMID: 36853469.
6. Thirasastr P, Somaiah N. Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors. Clin Exp Gastroenterol 16:11-19, 2023. e-Pub 2023. PMID: 36798653.
7. Thirasastr P, Brahmi M, Dufresne A, Somaiah N, Blay JY. New Drug Approvals for Sarcoma in the Last 5 Years. Surg Oncol Clin N Am 31(3):361-380, 2022. e-Pub 2022. PMID: 35715139.
8. Schvartsman G, Wagner MJ, Zobniw CM, Trinh VA, Patel S, Somaiah N. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Curr Oncol Rep 18(8):49, 2016. e-Pub 2016. PMID: 27319943.
9. Aggarwal C, Somaiah N, Simon GR. Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?. J Natl Compr Canc Netw 8(7):822-32, 2010. e-Pub 2010. PMID: 20679541.
10. Somaiah N, von Mehren M. New therapeutic approaches for advanced gastrointestinal stromal tumors. Hematol Oncol Clin North Am 23(1):139-50, x, 2009. e-Pub 2009. PMID: 19248977.

Professional Educational Materials

1. Nassif E, MD, Somaiah N, MD. ASCO Daily News Article: Improving the Benchmark: Examining ASCO22 Histology-Specific Trials in Sarcoma, 2022.
2. Somaiah N. ASCO Daily News Article: Rare Cancers-sarcoma commentary - Virtual Scientific Program. Rare Cancers-sarcoma commentary post-ASCO 2021 virtual Scientific Program, 2021.
3. Somaiah N. ASCO 2020 Abstracts. Commentary on Sarcoma abstracts for Cardinal Health newsletter series on ASCO 2020 abstracts, 2020.
4. Zarzour MA, MD, Somaiah N, MD. ASCO Daily News Expert Panel. Highlights of New Sarcoma Research, 2020.
5. Somaiah N. VEGF - Targeting in Gastrointestinal Stromal Tumors, 2017.
6. Somaiah N. GIST Module. Clinical Care Options, 2015.

Other Articles

1. Somaiah N Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations. JAMA Oncol, 2027. PMID: 41746633.
2. Somaiah N Optimal Pairings with Broad Spectrum TKIs. ASCO 2023 Annual Meeting, 2023.
3. Symcox M, Somaiah N Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study. Future Oncol 17(36):5007-5012, 2021. PMID: 34661454.
4. Phyllis Pittman RB Sarcoma patient information. CmedED content review, 2021.

Abstracts

1. Denu R, Somaiah N. Prognostic and biologic significance of ATRX mutation in adult soft tissue sarcoma. 2025 CTOS Annual Meeting, 2025.
2. Somaiah N. Preclinical models unveil mechanism behind progression from well-differentiated (WD) to dedifferentiated (DD) liposarcoma. 2025 CTOS Annual Meeting, 2025.
3. Somaiah N. The role of socioeconomic disparities on survival outcomes in malignant peripheral nerve sheath tumors. 2025 CTOS Annual Meeting, 2025.
4. Somaiah N. Updated results from strategist 1: A phase 1/1b study of IDRX-42 (GSK6042981a) in patients (pts) with advanced gastrointestinal stromal tumors (GIST). 2025 CTOS Annual Meeting, 2025.
5. Somaiah N. A PH/2 study of the radiopharmaceutical [AC-225] RTX-2358 in the treatment of relapsed / refractory (R/R) soft tissue sarcoma (STS) the atlas study - actinium therapy for late-stage aggressive sarcomas. 2025 CTOS Annual Meeting, 2025.
6. Somaiah N. Immune profiling of undifferentiated pleomorphic sarcomas reveals distinct prognostic subgroups. 2025 CTOS Annual Meeting, 2025.
7. Somaiah N. MTAP in gastrointestinal stromal tumor (GIST): rate of MTAP loss and concordance between genomic sequencing and immunohistochemistry. 2025 CTOS Annual Meeting, 2025.
8. Nathenson, Hoch, Ireland, O'Nians Michalowicz, Williams, Somaiah N. Pooled analysis of trabectedin efficacy in myxoid/round cell liposarcoma from three prospective clinical trials. 2025 CTOS Annual Meeting, 2025.
9. Wannaphut, Somaiah. Racial disparities in incidence and mortality over 20 years among AYA patients with sarcoma in the us: A seer database analysis. 2025 CTOS Annual Meeting, 2025.
10. Wannaphut C, Somaiah N. Treatment outcomes of gemcitabine and docetaxel in patients with clear cell sarcoma (ccs) or gastrointestinal neuroectodermal tumor (GNET): a case series. 2025 CTOS Annual Meeting, 2025.
11. Somaiah N. Outcomes of later-lines systemic therapies in malignant peripheral nerve sheath tumors (MPNST). 2025 CTOS Annual Meeting, 2025.
12. Somaiah N. Outcomes of multimodal perioperative treatment in osteosarcomas of the jaw. 2025 CTOS Annual Meeting, 2025.
13. Oliva-Ramirez J, Stanford MD, Lu H, Lee Y, Tomczak K, Rosales MM, Zhou X, Ravi V, Conley A, Ingram D, Deboever N, Strange CD, Weissferdt A, Rice DC, Zhang J, Ludwig J, Amaria R, Livingston J, Altan M, Mehran RJ, Somaiah N, Tsao A, Haymaker C. Identification of metabolic profiles from expanded tumor infiltrating lymphocytes across multiple cancer types. SITC 2024 Metabolism at the Hub of Cancer Immunity,, 2024. e-Pub 2024.
14. Heinrich MC, Somaiah N, Trent JC, Wilky BA, Burgess MA, Singh AS, Attia S, Agulnik M, Tap WD, Bauer S, Jones RL, Serrano C, Zou L, Moynihan K, Lawrence J, Wagner AJ. Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST). 2024 ASCO Gastrointestinal Cancers Symposium, 2024. e-Pub 2024.
15. Gingrich AA, Beird H, Chu R, Traweek R, Cope B, Keung EZ, Scally C, Hunt K, Torres KE, Roland C, Futreal PA, Bishop AJ, Guadagnolo BA, Mitra D, Farooqi AS, Araujo DM, Zarzour M, Livingston A, Conley AP, Patel SS, Ravi V, Somaiah N, Lazar AJ, Ratan R, Nassif E. Leiomyosarcoma Intratumoral Macrophage Infiltrates Are Associated With Distinct Clinical And Genomic Presentations. CTOS 2023 Annual Meeting, 2023. e-Pub 2023.
16. Roszik J, Denu RA, Nassif EF, Nakazawa M, Livingston A, Akdemir KC, Ratan R, Lazar AJ, Wang WL, Pestana R, Farooqi AS, Roland C, Keung EZ, Ravi V, Somaiah N, Patel S, Conley AP. TP53 Alterations In Sarcomas: An Analysis From The AACR-Genie Database. CTOS 2023 Annual Meeting, 2023. e-Pub 2023.
17. Bishop AJ, Mitra D, Farooqi AS, Hempel C, Bagchi C, Willis T, Pearlnath C, Wang WL, Ratan R, Somaiah N, Benjamin R, Torres KE, Hunt K, Scally C, Satcher Jr RL, Bird J, Lin P, Moon B, Lewis V, Roland C, Guadagnolo BA. Long-Term Disease Outcomes, Late Toxicity, And Function Following Hypofractionated Preoperative Radiation Therapy For Patients With Soft Tissue Sarcomas: A Hyport-STS Update. CTOS 2023 Annual Meeting, 2023. e-Pub 2023.
18. Bauer S, Blay JV, Chi P, Jones RL, Serrano C, Somaiah N, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Heinrich MC, George S. INSIGHT: A Phase 3, Randomized, Open-Label Study Of Ripretinib VS Sunitinib In Patients With Advanced Gastrointestinal Stromal Tumor Previously Treated With Imatinib With KIT Exon 11+17/18 Mutations. CTOS 2023 Annual Meeting, 2023. e-Pub 2023.
19. Somaiah N, Heinrich MC, Trent J, Wilky BA, Burgess M, Singh A, Attia S, Agulnik M, Tap WD, Bauer S, Jones RL, Serrano C, Liangxing Z, Moynihan K, Lawrence J, Wagner AJ. PEAK STUDY: A Phase 3, Randomized, Open-Label Multicenter Clinical Study Of Bezuclastinib (CGT9486) And Sunitinib Combination Versus Sunitinib In Patients With Gastrointestinal Stromal Tumors (GIST). CTOS 2023 Annual Meeting, 2023. e-Pub 2023.
20. Merriam P, Mazzola E, Chi P, Chen A, Agulnik M, Burgess M, Schuetze SM, Somaiah N, Tine V, BA Pollack S, Tinoco G, Trent J, Wilky BA, Bothwick N, Piekarz R, Hemming ML, Bernstein B, Shapiro GI, Demetri G, George S. A Phase 2 Study Of Rogaratinib (BAY 1163877) In Soft Tissue Sarcomas: Initial Results In Cohort Of Patients With Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumor (GIST). CTOS 2023 Annual Meeting, 2023. e-Pub 2023.
21. Livingston A, Cloutier J, Conley AP, Gorlick R, Benjamin R, Posey K, Nassif E, Zarzour M, Araujo DM, Ratan R, Ravi, V, Somaiah N, Lin H, Leung CH, Lazar AJ, Lewis V, Lin P, Amini B, Valenzuela RF, Patel S, Wang, WL. Chemotherapy And Prognostic Significance Of Extent Of Dedifferentiation In Dedifferentiated Parosteal Osteosarcoma. CTOS 2023 Annual Meeting, 2023. e-Pub 2023.
22. Denu RA, Joseph C, Urquiola E, Byrd P, Ratan R, Zarzour M, Conley AP, Araujo DM, Ravi V, Patel S, Wang WL, Lazar AJ, Somaiah N. Clinico-Genomic Analysis of KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors Identifies Potential Driver Mutations. CTOS 2023 Annual Meeting, 2023. e-Pub 2023.
23. Nassif EF, Beird H, Mitra A, Liu B, McBride K, Wang WL, Ingram DR, Wani K, Keung EZ, Mosaic Team RTITP, Zarzour M, Conley AP, Araujo DM, Livingston A, Ratan R, Patel S, Ravi V, Benjamin R, Lazar AJ, Roland C, Futreal PA, Somaiah N. Histology Specific Intratumoral B-Cell Biology In Alveolar Soft-Part Sarcomas (ASPS) In Response To Durvalumab-Tremelimumab (D-T). CTOS 2023 Annual Meeting, 2023. e-Pub 2023.
24. Torres MB, Leung CH, Keung EZ, Feng C, Zarzour M, Scally C, Hunt K, Conley AP, Bishop AJ, Guadagnolo BA, Farooqi AS, Mitra D, Araujo DM, Livingston A, Ratan R, Patel S, Ravi V, Lazar AJ, Roland C, Somaiah N, Nassif EF. Dedifferentiated Liposarcomas Treated With Immune Checkpoint Blockade: The MD Anderson Experience. CTOS 2023 Annual Meeting, 2023. e-Pub 2023.
25. Somaiah N, Van Tine BA, Chmielowski B, Drabick JJ, Chawla SP, McKean M, Spira AI, O'Byrne KJ, Foresto SA, Movva S, Kim A, Gastman B, Pressey JG, Paudyal B, De A, Winkler RE, Li M, Ahmad M, Yang D, Zhai Y. A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST). ASCO 2023 Annual Meeting, 2023. e-Pub 2023.
26. George S, Blay J, Chi P, Jones RL, Serrano C, Somaiah N, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S. INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations. ASCO 2023 Annual Meeting, 2023. e-Pub 2023.
27. Tap WD, Wagner AJ, Bauer S, Heinrich MC, Jones RL, Serrano C, Mehren MV, Somaiah N, Andor T, Zou L, Exter B, Lawrence J, LaHaie C, Mitchell S, Moynihan K, Sachs J, Sun L, Trent JC. Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study. ASCO 2023 Annual Meeting, 2023. e-Pub 2023.
28. Thirasastr P, Lin HY, Nassif EF, Wang W, Araujo DM, Benjamin RS, Conley AP, Livingston J, Ludwig JA, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Clinical implications of recurring mutations in myxoid liposarcoma (MLS). ASCO 2023 Annual Meeting, 2023. e-Pub 2023.
29. Manoj C, Nassif E, Deboever N, Damania A, Chen, Leung CH, Keung EZ, Wu C, Witt R, White M, Johnson S, Wong M, Mishra A, Lastrapes M, Somaiah N, Kadara H, Basu S, Allison J, Sharma P, McBride K, Fridman WH, Heymach JV, Sepesi B, Ajami N, Roland CL, Wargo JA, Cascone T. Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers. SITC 2023 Spring Scientific, Host Immunity in Immunotherapy Responses: From Discoveries to Precision Oncology(Abstract ID: 330987), 2023. e-Pub 2023.
30. Gill J, Conley AP, Somaiah N, Araujo DM, Ratan R, Posey K, Benjamin RS, Patel S, Daw NC, Harrison DJ, Gorlick R, Lin H, Wang W, Amini B, Gordon N, Livingston J. A Phase 1/2 Trial of Gemcitabine, Docetaxel, and Hydroxychloroquine in Advanced / Metastatic Osteosarcoma: Results of Phase 1. CTOS 2022 Annual Meeting, 2022. e-Pub 2022.
31. Traweek RS, MD, Somaiah N, MD. Dietary fiber intake is associated with increased tertiary lymphoid structures in dedifferentiated liposarcoma following immune checkpoint blockade. SITC 37th Annual Meeting & Pre-Conference Programs(248666), 2022. e-Pub 2022.
32. Ludwig, Joseph, Lee, Younghee, Rodriguez, Rebeca, Somaiah, Neeta, Livingston, Andrew J, Ingram, Davis R, Haymaker, Cara, Tomczak, Katarzyna J. The dual function of the adenosine pathway in Liposarcoma microenvironment. SITC 2022 Annual Meeting, 2022. e-Pub 2022.
33. D'Angelo SP, Druta M, Van Tine BA, Liebner DA, Schuetze S, Nathenson M, Holmes AP, D'Souza J, Kapoor GS, Zajic S, Center NS. Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS). ASCO 2022 Annual Meeting, 2022. e-Pub 2022.
34. Thirasastr P, Joseph C, Araujo DM, Benjamin RS, Conley AP, Livingston J, Ludwig JA, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Outcomes in late-line systemic treatment in GISTs: Does sequence matter?. ASCO 2022 Annual Meeting, 2022. e-Pub 2022.
35. George :S, Heinrich MC, Somaiah N, Van Tine BA, McLeod R, Laadem A, Cheng B, Nishioka S, Kundu MG, Qian X, Lau YY, Tran B, Kumar P, Dosunmu O, Shi J, Naito Y. A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST). ASCO 2022 Annual Meeting, 2022. e-Pub 2022.
36. McKean M, Tolcher AW, Reeves JA, Chmielowski B, Shaheen MF, Beck JT, Orloff MM, Somaiah N, Van Tine BA, Drabick JJ, Spira AI, O'byrne K, Karapetis CS, Foresto SA, Movva S, Martinez J, Li M, Winkler R, Yang D, Zhai Y. Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors. ASCO 2022 Annual Meeting, 2022. e-Pub 2022.
37. Somaiah N, Livingston J, Ravi V, Lin HY, Amini B, Solis LM, Conley AP, Zarzour MA, Ludwig JA, Ratan R, Wang W, Araujo DM, Patel S, Roland CL, Lazar AJ, Gorlick RG, Parra ER, Haymake CL. A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes. ASCO 2022 Annual Meeting, 2022. e-Pub 2022.
38. Lyu HG, Lillemoe HA, Chiang Y, Keung EZ, Nguyen ST, Peterson SK, Torres KE, Hunt K, Feig BW, Bishop AJ, Guadagnolo BA, Somaiah N, Roland CL, Scally C. Health-related quality of life in patients with resectable undifferentiated pleomorphic sarcoma treated with neoadjuvant checkpoint blockade in a single institution randomized phase II clinical trial. ASCO 2022 Annual Meeting, 2022. e-Pub 2022.
39. Nassif EF, Chelvanambi M, Chen L, Wu C, Damania A, Keung EZ, Witt RG, White M, Ajami NJ, Wong MC, Somaiah N, Sepesi B, Basu S, Allison JP, Sharma P, McBride K, Fridman W, Wargo JA, Cascone T, Roland CL. Identifying gut microbial signatures associated with B cells and tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) in response to immune checkpoint blockade (ICB). ASCO 2022 Annual Meeting, 2022. e-Pub 2022.
40. Nakazawa M, Livingston J, Bishop AJ, Zarzour MA, Somaiah N, Ratan R, Gill JB, Urquiola E, Posey K, Guadagnolo BA, Gorlick RG, Benjamin RS, Patel S, Conley AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma (ARMS) patients on front-line therapies: An MD Anderson Cancer Center (MDACC) case series. ASCO 2022 Annual Meeting, 2022. e-Pub 2022.
41. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, Moore JA, Yilmaz B, Karp DD, Dumbrava EE, Tsimberidou AM, Hong DS, Ahnert JR, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F, Cancer Center UOTMA, Houston, TX, Medical Center TUOTS, Dallas, TX, Cancer Center TUOTMA, Houston, TX, Cancer Therapeutics DOI, Cancer Center TUOTMA, Houston, TX, Cancer Therapeutics DOI, Cancer Medicine DO, Cancer Center TUOTMA, Houston, TX, Cancer Center UOTMA, Medical Oncology DOS, Houston, TX, Center MD, Houston, TX. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple negative breast cancer. ASCO 2022 Annual Meeting, 2022. e-Pub 2022.
42. Keung EZ, Nassif EF, Lin HY, Lazar AJ, Torres KE, Wang W, Guadagnolo BA, Bishop AJ, Hunt K, Feig BW, Bird JE, Lewis VO, Ratan R, Patel S, Zelazowska M, Liu B, McBride K, Wargo JA, Roland CL, Somaiah N. Randomized phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS): Survival results after 2 years of follow-up and intratumoral B-Cell Receptor (BCR) correlates. ASCO 2022 Annual Meeting, 2022. e-Pub 2022.
43. Thanh Nguyen TD, Pina MA, Wang Y, Karakas C, Bui TN, Mawlawi O, Lazar AJ, Ingram DR, Lazcano Segura RN, Hougton PJ, Somaiah N, Hunt KK, Keyomarsi K. Early proliferative response via 18FLT-PET/CT and serum TK1 activity are predictive biomarkers for synergistic effect of sequential cell cycle targeted therapy in sarcoma. AACR 2022 Annual Meeting, 2022. e-Pub 2022.
44. Thirasastr, Amini B, Lin H, Roland C, Feig B, Keung E, Nassif E, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour A, Zhou X, Somaiah N. Efficacy of Gemcitabine- Docetaxel in Dedifferentiated Liposarcoma. Poster Discussion. CTOS 2021 Virtual Meeting, 2021. e-Pub 2021.
45. Keung E, Nassif E, Lin H, Lazar A, Wang W, Parra E, Lima C, Wistuba I, Guadagnolo A, Bishop A, Lewis V, Torres K, Hunt K, Feig B, Scally C, Rawi AA, Crosby S, Mathew G, Ingram D, Wani K, Wargo J, Somaiah N, Roland C. Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma (STS) treated with neoadjuvant immune checkpoint blockade (ICB). SITC 36th Annual Meeting & Pre-Conference Programs, 2021. e-Pub 2021.
46. D'Angelo SP, Druta M, Van Tine BA, Liebner DA, Schuetze S, Hasan AN, Holmes AP, Huff A, Kapoor GS, Zajic S, Somaiah N. Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): interim analysis. CTOS 2021 Virtual Meeting, 2021. e-Pub 2021.
47. Kapoor G, Zajic S, Suchindran S, Kim J, Eleftheriadou I, Huff A, Nathenson M, Druta M, Tine BV, Somaiah N, Liebner D, Schuetze S, D’Angelo S.  Biomarker correlates of response in patients with advanced myxoid/round cell liposarcoma (MRCLS) treated with NY-ESO-1 TCR T cells (Letetresgene autoleucel). SITC 36th Anniversary Annual Meeting (SITC 2021) Abstracts 9(Suppl 2), 2021. e-Pub 2021.
48. Zalcberg JR, Heinrich MC, George S, Bauer S, Schoffski P, Serrano C, Jones RL, Gelderblom H, Attia S, D'Amato GZ, Chi P, Reichardt P, Somaiah N, Meade JN, REICHERT VL, Shi K, Sherman ML, Ruiz-Soto R, Mehren MV, Blay J. Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study. ASCO 2021 Virtual Annual Meeting (Deciphera Pharmaceuticals LLC), 2021. e-Pub 2021.
49. Van Tine BA, Chawla SP, Trent JC, Wilky BA, Chugh R, Chmielowski B, Kummar S, Mallick AB, Somaiah N, Cranmer LD, Agulnik M, Keedy VL, Stacchiotti S, Vincenzi B, Badalamenti G, Siontis BL, Attia S. A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma. ASCO 2021 Virtual Annual Meeting, 2021. e-Pub 2021.
50. Tolcher AW, Reeves JA, McKean M, Chmielowski B, Beck JT, Shaheen MF, Somaiah N, Wilson M, Spira AI, Drabick JJ, Tang Y, Winkler R, Li M, Ahmad M, Lu M, Liang Z, Yang D, Zhai Y. Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs. ASCO 2021 Virtual Annual Meeting (Ascentage Pharma Group LTD, Hong Kong), 2021. e-Pub 2021.
51. George S, Janku F, Chi P, Mehren MV, Somaiah N, Gelderblom H, Jones RL, Allard M, Taylor A, Li X, Meade J, Reichert V, Ruiz-Soto R, Wang J, Heinrich M. Population pharmacokinetics of ripretinib in patients with advanced malignancies. AACR 2021 Virtual Annual Meeting, 2021. e-Pub 2021.
52. Meric-Bernstam, Funda, Somaiah, Neeta, Janku, Filip, Piha-Paul, Anne S, Ahnert R, Jordi, Pant, Shubham. Whole exome sequencing of tumor tissue and circulating tumor DNA ingastrointestinal stromal tumors (GIST). AACR Virtual Annual Meeting 2021(Abstract Control Number: 5360), 2021. e-Pub 2021.
53. George S, Chi P, Heinrich M, vonMehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Razak AA, Gordon M, Somaiah N, Jennings J, Shi K, Ruiz-Soto R, Janku F. Ripretinib intra-patient dose escalation following disease progression provides meaningful PFS in GIST phase 1 study. CTOS. CTOS 2020 Virtual Meeting, 2020. e-Pub 2020.
54. Keung EZ, Nassif EF, Lin H, Lazar AJ, Wang W, Cuentas EP, Wistuba I, Guadagnolo B, Bishop AJ, Lewis V, Torres KE, Hunt KK, Feig BW, Scally CP, Al Rawi AN, Crosby S, Mathew G, Ingram D, Wani K, Wargo JA, Somaiah N, Roland CL. Sarcoma immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma treated with neoadjuvant immune checkpoint blockade (ICB). SITC 2020 Annual Meeting, 2020. e-Pub 2020.
55. Gounder M, Razak A, Somaiah N, Martin-Broto J, Schuetze S, Grignani G, Chawla S, Chmielowski B, Vincenzi B, Stacchiotti S, Wagner AJ, Cesne AL, Riedel RF, Jones RL, Ganjoo KN, del Muro XG, Burgess MA, Michel D, Wang H, Shah JJ, Attia S. A Phase 2/3, Randomized, Double Blind, Cross-Over, Study of Selinexor versus Placebo in Advanced Unresectable DeDifferentiated Liposarcoma (DDLS). CTOS 2020 Virtual Meeting, 2020. e-Pub 2020.
56. Nathenson M, Somaiah N, Hsu R, DeMaria PJ, Catoe H, Subhawong T, Amini B, Sweet K, Pang A, Hu J, Sheren J, Rosenberg A, Lazar A, Ratan R, Ravi V, Patel S, Maki R, Benedetto P, Cohen J, Trent J, Wilky B. Association of CTNNB1 mutation subtypes with responses to systemic therapy in patients with desmoid tumors: A multi-institutional retrospective study. CTOS 2020 Virtual Meeting, 2020. e-Pub 2020.
57. Roland C, Keung E, Lazar A, Torres K, Wei-Lien W, Guadagnolo A, Bishop A, Lin H, Hunt K, Feig B, Bird J, Lewis V, Tawbi H, Ratan R, Patel S, Wargo J, Somaiah N. Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). J Clin Oncol, ASCO Virtual Scientific Program 2020(38), 2020. e-Pub 2020.
58. Somaiah N, Conley AP, Lin HY, Amini B, Sabir SH, Araujo DM, Benjamin RS, Livingston J, Patel S, Ratan R, Ravi V, Zarzour MA, Wang W, Tate T, Roland CL, Daw NC, Futreal A, Lazar AJ, Wistuba II, Hwu P. A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes. 2020 ASCO Virtual Scientific Program, 2020. e-Pub 2020.
59. Attia S, Pollack S, Van Tine BA, Chawla S, Druta M, Burgess M, Bohac G, Somaiah N. Clinical outcomes from a retrospective registry of patients with locally advanced/metastatic synovial sarcoma and myxoid round cell liposarcoma. J Clin Oncol, ASCO Annual Meeting 2019(37), 2019. e-Pub 2019.
60. Somaiah N, Van Tine BA, Goodwin-Hill E, Milhem M. Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS). J Clin Oncol, ASCO Annual Meeting 2019(37), 2019. e-Pub 2019.
61. von Mehren M, Litwin S, Vinod R, Schuetze S, Movva S, Agulnik M, Kraft A, Tetzlaff E, Somaiah N. Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS). J Clin Oncol, ASCO Annual Meeting 2019(37), 2019. e-Pub 2019.
62. D'Angelo S, Druta M, Liebner D, Schuetze S, Somaiah N, Van Tine B, Tap W, Pulham T, Chagin K, Norry E, Amado R. Pilot study of NY-ESO-1c259T cells in advanced myxoid/round cell liposarcoma. ASCO 2018 Annual Meeting, 2018. e-Pub 2018.
63. Somaiah N, Chawla SP, Block MS, Morris JC, Do KT, Kim JW, Druta M, Sankhala KK, Hwu P, Gnjatic S, Lu H, Kenney RT, Bohac GC, Pollack S. Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS). J Clin Oncol, ASCO Annual Meeting 2017, 2017. e-Pub 2017.
64. Pollack S, Lu H, Somaiah N, Chawla SP, Morris JC, Do KT, Kim JW, Block MS, Vignali M, Rytlewski J, Yusko E, Hsu FJ, Bohac GC, Gnjatic S. Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients. J Clin Oncol 35, 2017. e-Pub 2017.
65. D'Angelo SP, Druta M, Demetri GD, Liebner DA, Schuetze S, Singh AS, Somaiah N, Van Tine BA, Wilky BA, Chagin K, Pulham T, Iyengar M, Norry E, Bartlett-Pandite AN, Amado RG. A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743). J Clin Oncol 35, 2017. e-Pub 2017.
66. Livingston JA, Posey K, Subbiah V, Daw NC, Somaiah N, Ravi V, Patel S, Benjamin RS, Wang W, Lazar A, Broaddus R, Meric-Bernstam F, Shaw KR, Roszik J, Conley AP. Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations. J Clin Oncol 35, 2017. e-Pub 2017.
67. Janku F, Abdul Razak AR, Gordon MS, Brooks DG, Flynn DL, Kaufman M, Pitman J, Smith BD, Somaiah N, De Groot JF, Chen G, Jennings J, Salah S, Westwood D, Gerstenberger E, Rosen O, George S. Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors. J Clin Oncol 35, 2017. e-Pub 2017.
68. Conley A, Wang WL, Ravi V, Roland C, Somaiah N, Hwu P, Yee C, Futreal A, Lazar A, Rosnik J. MAGEA3 Expression & Clinical Correlation In Sarcoma Subtypes. Connective Tissue Oncology Society 2016, 2016. e-Pub 2016.
69. Conley A, Ravi V, Somaiah N, Patel SR, Benjamin RS, Zarzour MA, Ludwig JA, Araujo D, Huh W, Subbiah V. Safety, Toxicity, & Activity of Multi-Kinase VEGFR TKI Vandetanib Combined with MTOR Inhibitor Everolmus in an Advanced Sarcomas Cohort of a Phase I Study. Connective Tissue Oncology Society 2016, 2016. e-Pub 2016.
70. Nathenson M, Ravi V, Lin H, Wang WL, Lazar A, Araujo D, Somaiah N, Zarzour MA, Ratan R, Patel SR, Benjamin RS, Conley A. The Role of Estrogen and Progesterone as Prognostic Factors for Adenosarcoma of the Uterus. Connective Tissue Oncology Society 2016, 2016. e-Pub 2016.
71. Schvartsman G, Wagner M, Barbo A, Lin H, Amini B, Trinh V, Wang WL, Patel SR, Benjamin RS, Somaiah N, Cancer Center TUOTMA. The Toxicity & Efficacy Profile of Regorafenib (RG) in Gastrointestinal Tumor (GIST) Patients Using An Alternate Dosing Regimen. Connective Tissue Oncology Society 2016, 2016. e-Pub 2016.
72. Subbiah V, Anerson P, Kairemo K, Huh W, Ravi V, Daw N, Somaiah N, Benjamin B, Hong D, Macapinlac H, Ravizzini G, Rohren E. Alpha particle radium-223 dichloride (223RaCI2) therapy and personalized molecular imaging with bone scintigraphy, NAF-PET and FDG-PET in high risk osteosarcoma. Connective Tissue Oncology Society 2016, 2016. e-Pub 2016.
73. Yu J, Wu C, Beird H, Bovee J, Lazar A, Somaiah N, Nielsen T. Myxoid Liposarcoma Fusion Protein FUS-DDIT3 Associates with PARP1, RNA Processing & DBHS Family Proteins (SFPS, NONO, PSPC1). Connective Tissue Oncology Society 2016, 2016. e-Pub 2016.
74. Nathenson MJ, Conley AP, Lin HY, Wang WL, Lazar A, Araujo D, Somaiah N, Zarzour MA, Ratan R, Patel SR, Benjamin RS, Ravi V. Prognostic Factors for Adenosarcoma of the Uterus. Connective Tissue Oncology Society 2016, 2016. e-Pub 2016.
75. Stacchiotti S, Mir O, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Brhami M, Boye K, Hindi N, Paterczyk HK, Italiano A, Kobayashi E, Provenzo S, Kawai A. Pazopanib (P) and Trabectedin (T) in alveolar soft part sarcoma (ASPS). Connective Tissue Oncology Society 2016, 2016. e-Pub 2016.
76. Somaiah N, Block MS, Kim JW, Shapiro G, Do KT, Hwu P, Eder JP, Jones RL, Gnjatic S, Lu H, Meulen JT, Hsu FJ, Pollack S, Cancer Center TUOTMA, Houston, TX, Clinic M, Rochester, MN, Cancer Center YU, Haven N, CT, Institute DC, Boston, MA, Research Center FHC, Seattle, WA, Mount Sinai ISOMA, York N, NY, Design I, Seattle, WA. Single-agent LV305 to induce anti-tumor immune & clinical responses in patients with advanced or metastatic sarcoma. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016. e-Pub 2016.
77. Gounder MM, Bauer TM, Schwartz GK, Masters T, Carvajal RD, Song S, Kumar P, Gajee R, Zernovak O, Rosen MM, Kochan JP, Chen S, Hyman DM, Gokmen S, Meric-Bernstam F, LoRusso P, Somaiah N, Weise AM, Hong DS. A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors & lymphoma. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016. e-Pub 2016.
78. Dembla V, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Meric-Bernstam F, Subbiah V. Outcomes of patients with advance sarcoma enrolled in clinical trials of pazopanib in combination of histone deacetylase. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016. e-Pub 2016.
79. Farag S, Somaiah N, Choi H, Heeres B, Wang W, Boven HV, Nederlof PM, Benjamin RS, der Graaf WTV, Grunhagen DJ, Boonstra P, Reyners AK, Gelderblom H, Steeghs N. Clinical characteristics & treatment outcome in a large multicenter observational cohort of pdgfraexon 18 mutated. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016. e-Pub 2016.
80. Gounder MM, Wagner AJ, Somaiah N, Riedel RF, Schwartz GK, Attia S, Razak AR, Cranmer LD, Okuno SH, Milhem MM, Choe-Juliak C, Shacham S, Kauffman MG, Chawla SP, Cancer Center MSK, York N, NY, Institute DC, Boston, MA, Cancer Center TUOTMA, Houston, TX, Medical Center DU, Durham, NC, Presbyterian Hospital CUMC-NY, York N, NY, Clinic M, Jacksonville, FL, Hospital PM, Toronto, ON, Canada, Cancer Center UOA, Tucson, AZ, Clinic M, Rochester, MN, Iowa Hospitals UO, Clinics, Cancer Center HC, City I, IA, Therapeutics K, Inc, Newton, MA, Director, Center SO, Monica S, CA. The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, mulit-center, randomized blind study. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016. e-Pub 2016.
81. Groisberg R, Hong DS, Janku F, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Conley AP, Herzog CE, Meric-Bernstam F, Subbiah V. Clinical next-generation sequencing in sarcomas. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016. e-Pub 2016.
82. Conley AP, Huh WW, Roszik J, Harrison DJ, Hayes-Jordan AA, Kehr KA, Ratan R, Somaiah N, Ravi V, Araujo DM, Zarzour MA, Ludwig JA, Wang W, Benjamin RS, Patel S. Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016. e-Pub 2016.
83. Subbiah V, Anderson PM, Kairemo K, Huh WW, Ravi V, Daw NC, Somaiah N, Benjamin RS, Hong DS, Ravizzini G, Rohren E. Alpha particle radium-223 dichloride (223RaCI2) in high risk osteosarcoma. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016. e-Pub 2016.
84. Nathenson M, Conley AP, Ratan R, Zarzour MA, Somaiah N, Araujo DM, Patel S, Benjamin RS, Ravi V. Efficacy of front-line chemotherapy for recurrent/metastatic Adenosarcoma of the uterus. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016. e-Pub 2016.
85. Conley AP, Huh WW, Roszik J, Harrison DJ, Hayes-Jordan AA, Kehr KA, Ratan R, Somaiah N, Ravi V, Araujo DM, Zarzour MA, Ludwig JA, Wang W, Benjamin RS, Patel S. Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies: An MD Anderson Cancer Center (MDACC) series. ASCO Annual Meeting, 2016. e-Pub 2016.
86. Subbiah V, MD, Anderson P, Huh WW, Ravi V, Hess K, Daw NC, Fernandez JG, Somaiah N, Ravizzini G, Sankhala K, Chawla SP, Schwartz CL, Hong DS, Rohren E. Safety and Feasibility of Alpha Particle Radium-223 Dichloride Therapy in High Risk Osteosarcoma: A Phase 1 Dose Escalation Trial. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015. e-Pub 2015.
87. Katz D, Lin H, Weaver N, Trent J, Hammerman A, PhD, Feldhamer I, Araujo D, Ravi V, Conley A, Wang W, Lazar A, Patel S, Benjamin R, Somaiah N. Predicting Response to Second-Line Sunitinib (SU) Based on Duration of Treatment on Front-Line Imatinib (IM) Patients with Metastatic GIST. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015. e-Pub 2015.
88. Somaiah N, Gilbert E, Conley A, Zarzour A, Patel S, Benjamin R, Bhosle P, Lin H, Watson K, Feig B, Torres KE, Roland C. PET/CT Imaging Might Be Superior to Percutaneous Biopsy in Identifying Dedifferentiation in Patients with Well-Differentiated (WDLS)/Dediffer. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015. e-Pub 2015.
89. Samuels B, MD, Chawla SP, Somaiah N, Staddon A, Skubitz KM, Mulvey K, Milhem M, Kaiser P, Portnoy D, Priebat D, Walker M, Stepanski E. Phase II Study of Pazopanib in Patients with Advanced Intermediate of High-Grade Liposarcoma. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015. e-Pub 2015.
90. de Graaff MA, MD, Malu S, Kruisselbrink A, Guardiola I, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovee J. Identification of Novel Drugable Targets for the Treatment of Myxoid Liposarcomas. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015. e-Pub 2015.
91. Somaiah N, Block MS, Kim JW, Shapiro G, Hwu P, Eder JP, Jones RL, Gnjatic S, Lu H, Hsu FJ, Pollack S. Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015. e-Pub 2015.
92. Somaiah N, Beird H, Shaw KR, Wang W, Conley AP, Ravi V, Torres KE, Ingram D, Roland CL, Subbiah V, Feig BW, F Lazar AJ, Benjamin RS, Patel S, Hwu P, Futreal A, Meric-Bernstam F, Hong DS. Targeted next generation sequencing in well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015. e-Pub 2015.
93. Wagner M, Hess KR, Hong DS, Tang C, Naing A, Fu S, Janku F, Piha-Paul SA, Zinner R, Wheler JJ, Tsimberidou AM, Patel S, Somaiah N, Ravi V, Benjamin RS, Meric-Bernstam F, Subbiah V. Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015. e-Pub 2015.
94. Conley AP, Satcher RL, Wang W, F Lazar AJ, Fox PS, Lin PP, Moon B, Bird JE, Araujo DM, Ravi V, Somaiah N, Patel S, Benjamin RS, Lewis VO. Clinical characteristics and treatment outcomes of clear cell chondrosarcomas: MD Anderson Cancer Center Series. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015. e-Pub 2015.
95. Vadhan-Raj S, Ravi V, Zhou X, Araujo DM, Somaiah N, Conley AP, Daniel M, Benjamin RS, Patel S, Spasojevic I. Effects of fosaprepitan (Fosa) on ifosfamide (Ifex) metabolism in sarcoma patients (pts) receiving multi-day chemotherapy (CT) regimen on doxorubicin (Dox) and Ifex (AI): Randomized, cross-over study. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015. e-Pub 2015.
96. Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch HA, Fancourt C, Levonas A, Lam R, Meister A, Kemp RK, Knox C, Rose S, Hong DS. A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015. e-Pub 2015.
97. Mehra R, Turaka A, Meyer JE, Egleston BL, Tanvetyanon T, Pinder MC, Dilling TJ, Williams CC, Gray JE, Shirai K, Alpaugh R, Riordan D, Somaiah N, Shah PC, Scott WJ, Simon GR, Borghaei H. Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol, ASCO Annual Meeting 2015(33), 2015. e-Pub 2015.
98. Conley AP, Somaiah N, Torres KE, Benjamin RS, W-L W, Hwu P, Patel S, Rohren E. Predicting survival using FDG pet responses in patients with unclassified sarcoma. Connective Tissue Oncology Society (CTOS) Berlin, 2014. e-Pub 2014.
99. Subbiah V, Patel S, Benjamin RS, Agarwal R, Janku F, Ludwig J, Anderson PM, Araujo D, Ravi V, Conley AP, Somaiah N, Naing A, Hong DS, Meric-Bernstam F. Targeted-Based therapeutic matching in early-phase clinical trials in patients with advanced sarcoma. Connective Tissue Oncology Society (CTOS) Berlin, 2014. e-Pub 2014.
100. Ravi V, Ramesh N, Patnana M, Conley AP, Somaiah N, Lazar AJ, Araujo D, Torres KE, Ali S, Miller VA, Benjamin RS. Targeted sequencing of leiomyosarcomas in the clinic: Potential for target identification. Connective Tissue Oncology Society (CTOS) Berlin, 2014. e-Pub 2014.
101. Conley AP, W-L W, Ravi V, Somaiah N, Subbiah V, Benjamin RS, Patel S. Clinical Outcomes for patients with metastatic, malignant granular cell tumors treated with systemic therapies. Connective Tissue Oncology Society (CTOS) Berlin, 2014. e-Pub 2014.
102. Somaiah N, Pollack SM, Wei-W, Araujo D, Amaria RN, Mittendon EA, Conley AP, Ravi V, Subbiah V, Benjamin RS, Patel S, Kenney R, Hsu F, Hwu P, Jones RL, Shapiro G, Kim JW, Block MM. Evaluating the safety and immunogenicity of IS-LV305, a third generation lentiviral vaccine in patients with ny-eso-1 positive malignancies. Connective Tissue Oncology Society (CTOS) Berlin, 2014. e-Pub 2014.
103. Livingston JA, Bugano D, Madewell J, W-L W, Conley AP, Ravi V, Araujo D, Tseng WW, Feig B, Torres KE, Benjamin RS, Somaiah, N. Assessing chemotherapy benefit in well-differentiated/De-differentiated liposarcoma. Connective Tissue Oncology Society (CTOS) Berlin, 2014. e-Pub 2014.
104. Jalal SI, Hanna NH, Zon R, Masters GA, Borghaei H, Koneru K, Badve SS, Prasad NK, Somaiah N, Wu J, Yu Z, Einhorn LH. Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: HOG LUN 07-130. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014. e-Pub 2014.
105. Somaiah N, Diniz Gomes DB, Madewell JE, Wang W, Conley AP, Ravi V, Araujo DM, Ludwig JA, Benjamin RS, Patel S. Defining the chemotherapy (CT) response in well-differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS) of the retroperitoneum (RP): A tertiary referral cancer center experience. American Society of Clinical Oncology (ASCO) Conference 2014, 2014. e-Pub 2014.
106. Ravi V, Ramesh N, Patnana M, Conley AP, Somaiah N, Zarzour MA, Ingram D, Little L, Protopopov A, F Lazar AJ, Araujo DM, Torres KE, Patel S, Zhang J, Ali SM, Miller VA, Stephens PJ, Benjamin RS, Hwu P, Futreal A. Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014. e-Pub 2014.
107. Vadhan-Raj S, Zhou X, Araujo DM, Somaiah N, Conley AP, Ravi V, Daniel M, Benjamin RS, Patel S. Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receiving multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosafamide (AI): Randomized cross-over study. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014. e-Pub 2014.
108. Subbiah V, Agarwal R, Janku F, Tsimberidou AM, Patel S, Benjamin RS, Ludwig JA, Anderson PM, Araujo DM, Ravi V, Conley AP, Somaiah N, Wang W, Naing A, Zinner R, Hong DS, Meric-Bernstam F. Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision medicine. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014. e-Pub 2014.
109. Tseng WW, Malu S, Zhang M, Somaiah N, Ingram D, Lev DC, Pollock R, Lizee G, Radvanyi L, Hwu P. A feasibility study and trial proposal of immune checkpoint blockage in well and dedifferentiated retroperitoneal liposarcoma. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013. e-Pub 2013.
110. Somaiah N, Raj S, Gupta R, Ravi V, Conley T, Araujo D, Benjamin R, Patel S, Banchs J, Vadhan-Raj S. Low incidence of cardiotoxicity noted with high-dose doxorubicin (A) at 90mg/m2/cycle given as a continuous infusion. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting (#1764432), 2013. e-Pub 2013.
111. Ravi V, Ramesh N, Somaiah N, Leja M, Conley P, Ludwig J, Araujo D, Taylor S, Torres K, Wang W, Hunt K, Reardon M, Benjamin R, Patel S. Cardiac angiosarcoma: Clinical features and treatment outcomes. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013. e-Pub 2013.
112. Tseng WWW, Madewell J, Wang W, Somaiah N, Lazar A, Ghadimi M, Hoffman A, Pisters P, Lev D, Pollock R. Analysis of locoregional disease patterns as a guide to the extent of resection in well differentiated and dedifferentiated retroperitoneal liposarcoma. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013. e-Pub 2013.
113. Somaiah N, Ingram D, Liu J, Bolshakov S, de Graaff M, Szuhai K, Aman P, Toress KE, Lev D, Nielsen T, Bovee J, Lazar AJ. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013. e-Pub 2013.
114. Held-Warmkessel J, Davey M, Litwin S, Lee J, Smith MR, Millenson M, Cohen AD, Somaiah N, Hudes GR, Plimack ER, Wong YN, Kim S, von Mehren M. Observational study of ifosamide (Ifos) neurotoxicity (N): The prospective use of a nursing assessment tool. J Clin Oncol, ASCO Annual Meeting 2012((#e19580)), 2012. e-Pub 2012.
115. Somaiah N, Simon GR, South Carolina MUO, Charleston, SC, Center HC, South Carolina MUO, Charleston, SC. An analysis of target-specific patient resource utilization in NSCLC clinical trials. J Clin Oncol, ASCO Annual Meeting 2012, 2012. e-Pub 2012.
116. Mehra R, Tuaka A, Meye J, inder-Schenck M, Shirai K, Somaiah N, Egleston B, Borghaei H, Simon G. Phase I study o vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer. NCCN 18th Annual Conference, 2012. e-Pub 2012.
117. Held-Warmkessel J, Davey M, Litwin S, Lee J, Smith MR, Millenson M, Cohen AD, Somaiah N, Hudes GR, Plimack ER, Wong YN, Kim S, von Mehren M. The prospective use of a nursing assessment tool. J Clin Oncol, ASCO Annual Meeting((#e19580)), 2012. e-Pub 2012.
118. Tap WD, Van Tine BA, Elias AD, Livingston MB, Agulnik M, Cooney MM, Chmielowski B, Brenner AJ, Pennock GK, Somaiah N, Dang LH, Tian GG, Jones RL, Okuno SH, Loizos N, Nippgen J, Schwarts GK. A phase lb/ll study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRa monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS). J Clin Oncol, ASCO Annual Meeting 2012, 2012. e-Pub 2012.
119. Jalal S, Bufill J, Guarino M, Somaiah N, Koneru K, McClean J, Nichols C, Wu J, Yu Z, Einhorn L. A phase I study of Amrubicin (AMR) and Cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group. J Clin Oncol, ASCO Annual Meeting 2011, 2011. e-Pub 2011.
120. Somaiah N, Garrett-Mayer E, Huang X, Wahlquist A, Danenberg K, Simon GR. Negative thyroid transcription factor (TTF-1) status predicts for negative epidermal growth factor receptor (EGFR) mutations (Mts) status with a high negative predictive value (NPV) in patients (pts) with adenocarcinomas (AC) of the lung. J Clin Oncol, ASCO Annual Meeting 2011 (poster discussion)(29), 2011. e-Pub 2011.
121. Scott WJ, Aggarwal C, Lebenthal A, Egleston B, Borghaei H, Mehra R, Somaiah N, Turaka A, Simon G, Cancer Center FC, Philadelphia, PA. Influence of surgical interventions on survival in patients with stage III non-small cell lung cancer (NSCLC): The Fox Chase Cancer Center (FCCC) experience. J Clin Oncol, ASCO Annual Meeting 2010(28:15s), 2010. e-Pub 2010.
122. Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, Davey M, Bove B, Godwin AK, von Mehren M. Evaluation of nilotinib in advanced GIST previously treated with imatinib mesylate and sunitinib. J Clin Oncol, ASCO Annual Meeting 2010(28:15s), 2010. e-Pub 2010.
123. Somaiah N, Al Saleem T, Watson JC, Scott WJ, Patchefsky A, von Mehren M. Comparing Intra-thoracic and Extra-thoracic Solitary Fibrous Tumors: a clinico-pathologic case series. 16th CTOS Annual Meeting, 2010. e-Pub 2010.
124. Aggarwal C, Egleston B, Li L, Mehra R, Borghaei H, Somaiah N, Turaka A, Lebenthal A, Scott W, Simon GR. Role of surgery in patients with stage IIIA non-small cell lung cancer (NSCLC): Lessons learned from a tertiary referral cancer center experience. J Clin Oncol, ASCO Annual Meeting 2010(28:15s), 2010. e-Pub 2010.
125. Reichardt P, Schöffski P, LoRusso P, Yamamoto N, Moreno V, Lugowska I, Lauer UM, Somaiah N, Hu C, Landsteiner HT, Jayadeva G, Gounder M. Phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: overall safety, and efficacy in patients (pts) with well-differentiated liposarcoma (WDLPS). ESMO Sarcoma and Rare Cancers.
126. Reichardt P, Schöffski P, LoRusso P, Yamamoto N, Moreno V, Lugowska I, Lauer UM, Somaiah N, Hu C, Landsteiner HT, Jayadeva G, Gounder M. Phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: overall safety, and efficacy in patients (pts) with well-differentiated liposarcoma (WDLPS). ESMO Sarcoma and Rare Cancers.
127. Munnangi P, Somaiah N. Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST). 2024 ASCO Annual Meeting.
128. Merriam P, James J Morrow MD, Mazzola E, Solimini NL, Gokhale PC, Chi P, Chen A, Agulnik M, Burgess M, Schuetze S, Somaiah N, Van Tine BA, Pollack S, Tinoco G, Trent J, Wilky B, Bothwick N, Jiwani S, Wu P, Pelosof L, Hemming M, Shapiro G, Demetri G, Bernstein B, George S. Fibroblast growth factor receptor (FGFR) inhibition demonstrates anti-tumor activity in succinate dehydrogenase deficient gastrointestinal stromal tumor (SDHd GIST). AACR Annual Meeting.

Book Chapters

1. Thirasastr P, Brahmi M, Dufresne A, Blay JY, Somaiah N. New Drug Approvals in the Last 5 Years for Sarcoma. In: Surgical Oncology Clinics, 2022.
2. Parkes A, Somaiah N. Chapter 8, Leiomyosarcoma. In: Sarcomas: Evidence-Based Diagnosis and Management, 2020.
3. Somaiah N, Gupta R, Patel S. Chapter on Gastrointestinal Stromal Tumors. In: Textbook of GI Oncology, 2017.
4. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2016.
5. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2014.
6. Somaiah N, Patel S. Soft Tissue Sarcoma. In: Cancer Consult: Expertise for Clinical Practice. John Wiley and Sons, 2014.
7. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2013.
8. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2012.
9. Somaiah N, von Mehren M. The Role of Tyrosine Kinase Inhibitors in the Treatment of Gastrointestinal Stromal Tumors. In: Medscape, 2008.